安諾其(300067.SZ)回購註銷約15.05萬股限制性股票
格隆匯1月7日丨安諾其(300067.SZ)公佈,此次回購註銷前公司總股本為9.31億股,此次回購註銷的股份總數為約15.05萬股,佔回購前公司總股本的0.0162%,此次回購註銷完成後公司總股本變更為9.3億股。
公司此次回購註銷共涉及8人,回購註銷的股份總數為約15.05萬股。其中:預留授予的激勵對象夏錦橋因個人原因離職而喪失激勵資格,回購數量共計1.95萬股,回購價格為2.2615元/股;首次授予的激勵對象顧豔明、曲廣磊等7人因個人原因離職而喪失激勵資格,回購數量共計約13.1萬股,回購價格為2.827元/股。
公司於 2020年1月7日在中國證券登記結算有限責任公司深圳分公司完成回購註銷。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.